Inside Gilead’s Community Oncology CAR-T Pilot

Jun 03 2024

• By Alaric DeArment

Listen to this article

Scrip sat down with Kite Pharma EVP Cindy Perettie to talk about the program that Gilead is running with Tennessee Oncology to bring CAR-T therapy into the community setting.

• Source: Shutterstock

Management of common but potentially serious and even fatal side effects of CAR-T cell therapies like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) has come a long way since entering the market. Now, Gilead Sciences, Inc. is piloting a partnership with community oncology centers to do much of the clinical legwork, enabling patients to receive CAR-T therapy closer to home instead of having to travel to academic medical centers.

The Foster City, CA-based drug maker introduced the partnership with Tennessee Oncology in the first quarter. “We've identified many critical...

More from Anticancer

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Dec 05 2025
• By Xu Hu
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer
Sep 24 2025
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.